Biomarkers in melanoma: staging, prognosis and detection of early metastases

References

• Clark WH Jr, Elder DE, Guerry DT et al A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Athol 15 (12), 1147–1165 (1984).
   PubMedGoogle Scholar
• Clark WH Jr, Elder DE, Guerry DT et al Model predicting survival in Stage I melanoma based on tumor progression. Natl Cancer Inst. 81(24), 1893–1904 (1989).
   Google Scholar
• ••Seminal paper demonstrating correlation ofgrowth patterns with metastatic potential and the superiority of multifactorial analysis to tumor thickness alone.
   Google Scholar
• Guitart J, Lowe L, Piepkorn M etal Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol 138(5), 603–608 (2002).
   Google Scholar
• Cook MG, Spatz A, Brocker EB, Ruiter DJ. Identification of histological features associated with metastatic potential in thin (.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC melanoma group. I Athol 197(2), 188–193 (2002).
   Google Scholar
• •Identifies histologic patterns in thin (biologic early, low risk) melanomas that correlate with metastasis.
   Google Scholar
• Meyers M, Balch CM. Diagnosis and treatment of metastatic melanoma. In: Cutaneous Melanoma. Balch CM, Houghton A, Sober A etal (Eds), Quality Medical Publishing Inc., St. Louis, MO, USA, 325–372 (1998).
   Google Scholar
• Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of Stage III and IV disease. jAm Acad. Dermatol 42(3), 480–489 (2000).
   Google Scholar
• Brenner S, Tamir E. Early detection of melanoma: the best strategy for a favorable prognosis. Clin. Dermatol 20(3), 203–211 (2002).
   PubMedGoogle Scholar
• Mackie R. Incidence, risk factors and prevention of melanoma. Eur. j Cancer 34\(Suppl. 3), S3—S6 (1998).
   Google Scholar
• Carlson JA, Slominski A, Linette G, Mihm CM Jr, Ross JS. Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Rev Mal Diagn. 3(2), 89–110 (2003).
   Google Scholar
• Geller AC, Sober AJ, Zhang Z etal Strategies for improving melanoma education and screening for men age 50 years: findings from the American Academy of Dermatological National Skin Cancer screening program. Cancer 95 (7), 1554–1561 (2002).
   Google Scholar
• •Demonstrated a higher predictive value for melanoma screening in men of 50 years of age or older with a history of changing mole or skin Types land 11 compared with all others. iiSlominski A, Wortsman J, Carlson AJ etal Malignant melanoma. Arch. Athol Lab. Ailed. 125(10), 1295–1306 (2001).
   Google Scholar
• Morton DL, Hsueh EC, Essner R etal Prolonged survival of patients receiving active immunotherapy with canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann. Sur. 236(4), 438–448 (2002).
   PubMed Web of Science ®Google Scholar
• Lotem M, Peretz T, Drize 0 eta]. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC Stages III and IV). The new American Joint Committee on Cancer. BE Cancer86(10), 1534–1539 (2002).
   Google Scholar
• Belli F, Testori A, Rivoltini L etal Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. j Clin. 0=1 20(20), 4169–4180 (2002).
   Google Scholar
• Atkins MB, Gollob JA, Sosman JA etal A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2 and IFN-alpha2b in patients with metastatic melanoma. Clin. Cancer Res. 8(10), 3075–3081 (2002).
   Google Scholar
• Hakansson A, Hakansson L, Gustafsson B etal Biochemotherapy of metastatic malignant melanoma on downregulation of cd28. Cancer Immunol Immunother. 51(9), 499–504 (2002).
   Google Scholar
• Jo° SS, Kim MS, Oh WS, Lee DI. Enhancement of nk cytotoxicity, antimetastasis and elongation effect of survival time in b16-f10 melanoma cells by oregonin. Arch. Pharm. Res. 25 (4), 493–499 (2002).
   Google Scholar
• Kirkwood JM, Richards T, Zarour HM etal Immunomodulatory effects of high-dose and low-dose interferon-a2b in patients with high-risk resected melanoma: the e2690 laboratory corollary of intergroup adjuvant trial el690. Cancer 95(5), 1101–1112 (2002).
   Google Scholar
• McClay EE Adjuvant therapy for patients with high-risk malignant melanoma. Semin. 0=1 29(4), 389–399 (2002).
   Google Scholar
• O'Day SJ, Kim CJ, Reintgen DS. Metastatic melanoma: chemotherapy to biochemotherapy. Cancer (2ntm19(1), 31–38 (2002).
   Google Scholar
• Thome SD, Loprinzi CL, Heldebrant MR Determination of potential adjuvant systemic therapy benefits for patients with resected cutaneous melanomas. Mayo Clin. Proc. 77(9), 913–917 (2002).
   Google Scholar
• •• Developed a model that more accurately assesses survival benefit for adjuvant therapy utilizing data of 17,600 melanoma patients and results of a meta-analysis of Eastern Co-operative Oncology Group studies. Prognostic information, such as found herein, could help patients make more informed decisions regarding their treatment options.
   Google Scholar
• Mills L, Tellez C, Huang S etal Fully human antibodies to MCAIVI/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 62(17), 5106–5114 (2002).
   Google Scholar
• Cascinelli N, Heerlyn M, Schneeberger A etal What is the most promising strategy for the treatment of metastasizing melanoma? Exp. Dermatol 9(6), 439–451 (2000).
   Google Scholar
• Slominski A, Paus R, Mihm MC. Inhibition of melanogenesis as an adjuvant strategy in the treatment of melanotic melanomas: selective review and hypothesis. Anticancer Res. 18(5B), 3709–3715 (1998).
   Google Scholar
• Slominski A, Wortsman J, Luger T, Paus R, Solomon S. Corticotropin releasing hormone and pro-opiomelanocortin involvement in the cutaneous response to stress. Physiol Rev 80(3), 979–1020 (2000).
   PubMed Web of Science ®Google Scholar
• Ruiter DJ, Spatz A, van den Oord JJ, Cook MG. Microstaging in cutaneous melanoma. J. Pallid 195(5), 525–529 (2001).
   Google Scholar
• Balch CM, Buzaid AC, Atkins MB etal A new American joint committee on cancer staging system for cutaneous melanoma. Cancer88(6), 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ etal Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.j Clin. Oncol 19 (16), 3635–3648 (2001).
   Google Scholar
• ••Revised staging scheme that moreprecisely defines prognosis and will improve stratification of patients for clinical trials.
   Google Scholar
• Ruiter DJ, Testori A, Eggermont AM, Punt CJ. The AJCC staging proposal for cutaneous melanoma: comments by the EORTC melanoma group. Ann. Oncol 12(1), 9–11 (2001).
   PubMedGoogle Scholar
• McMasters KM, Wong SL, Edwards MJ et al Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery130(2), 151–156 (2001).
   PubMedGoogle Scholar
• Gershenwald JE, Thompson W, Mansfield PF etal Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 Stage I or II melanoma patients.j Clin. Onto" 17(3), 976–983 (1999).
   Google Scholar
• Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur j Cancer 38(4), 511–516 (2002).
   Google Scholar
• Balch CM, Soong SJ, Gershenwald JE etal Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol 19(16), 3622–3634 (2001).
   Google Scholar
• ••Results of this extensive analysis highlight incremental differences in survival between progressive stages and were used to revise the AJCC melanoma staging system.
   Google Scholar
• Merkel S, Meyer T, Papadopoulos T etal Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer. Eur. j Cancer 38(4), 517–526 (2002).
   PubMedGoogle Scholar
• DiFronzo LA, Wanek LA, Morton DL. Earlier diagnosis of second primary melanoma confirms the benefits of patient education and routine postoperative follow-up. Cancer91(8), 1520–1524 (2001).
   PubMedGoogle Scholar
• Negrier S, Fervers B, Bailly C etal Cutaneous melanoma. BE J. Cancer 84 (Suppl. 2), 81–85 (2001).
   Google Scholar
• Gershenwald JE, Buzaid AC, Ross MI. Classification and staging of melanoma. Hematol Onto" Clin. North Am. 12(4), 737–765 (1998).
   Google Scholar
• Sober AJ, Chuang TY, Duvic M etal Guidelines of care for primary cutaneous melanoma. J. A117. Acad. Delmatol 45 (4), 579–586 (2001).
   Google Scholar
• Weiss M, Loprinzi CL, Creagan ET etal Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAIVIA 274(21), 1703–1705 (1995).
   PubMedGoogle Scholar
• Johnson RC, Fenn NJ, Horgan K, Mansel RE. Follow-up of patients with a thin melanoma. BE J. Surg. 86 (5), 619–621 (1999).
   Google Scholar
• Balch CM, Soong SJ, Bartolucci AA etal Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann. Sing 224(3), 255–263 (1996).
   Google Scholar
• McMasters KM, Reintgen DS, Ross MI etal Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. I Clin. Oncol 19 (11), 2851–2855 (2001).
   Google Scholar
• Thompson JE The Sydney melanoma unit experience of sentinel lymphadenectomy for melanoma. Ann. Sing Oncol 8\(Suppl. 9), 44S-47S (2001).
   Google Scholar
• Marghoob AA, Koenig K, Bittencourt FV, Kopf AW, Bart RS. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer staging. Cancer 88(3), 589–595 (2000).
   PubMedGoogle Scholar
• Masback A, Olsson H, Westerdahl J, Ingvar C, Jonsson N. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res. 11(5), 435–445 (2001).
   PubMedGoogle Scholar
• •Good review of clinical and pathologic factors in prognostic analysis.
   Google Scholar
• Karjalainen JM, Eskelinen MJ, Nordling S etal Mitotic rate and S-phase fraction as prognostic factors in Stage I cutaneous malignant melanoma. BE J. Cancer 77(11), 1917–1925 (1998).
   Google Scholar
• Kashani-Sabet M, Sagebiel RVV, Ferreira CM, Nosrati M, Miller JR 3rd. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch. Dermatol 137(9), 1169–1173 (2001).
   Google Scholar
• •Demonstrates that histologic findings of vascular invasion in the primary melanoma independently predicts for poor survival and metastasis.
   Google Scholar
• Straume 0, Sviland L, Akslen LA. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin. Cancer Res. 6(5), 1845–1853 (2000).
   Google Scholar
• •Both loss of p16 and increased Ki-67 index independently predict poor prognosis.
   Google Scholar
• Ramsay JA, From L, Iscoe NA, Kahn HJ. Mib-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J. Invest. Dermatol 105(1), 22–26 (1995).
   Google Scholar
• Korabiowska M, Brinck U, Middel P etal Proliferative activity in the progression of pigmented skin lesions, diagnostic and prognostic significance. Anticancer Res. 20(3A), 1781–1785 (2000).
   Google Scholar
• Day CL Jr, Sober AJ, Kopf AW etal A prognostic model for clinical Stage I melanoma of the trunk. Location near the midline is not an independent risk factor for recurrent disease. Am J. Sing. 142(2), 247–251 (1981).
   Google Scholar
• Day CL Jr, Sober AJ, Kopf AW etal A prognostic model for clinical Stage I melanoma of the lower extremity. Location on foot as independent risk factor for recurrent disease. Surgery 89(5), 599–603 (1981).
   PubMedGoogle Scholar
• Day CL Jr, Sober AJ, Kopf AW etal A prognostic model for clinical Stage I melanoma of the upper extremity. The importance of anatomic subsites in predicting recurrent disease. Ann. Sing. 193(4), 436–440 (1981).
   Google Scholar
• Salti GI, Kansagra A, Warso MA, Ronan SG, Das Gupta TK. Clinical node-negative thick melanoma. Arch. Surg. 137(3), 291–295 (2002).
   Google Scholar
• Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer 42(5), 2282–2292 (1978).
   PubMedGoogle Scholar
• Spatz A, Shaw HM, Crotty IKA, Thompson JF, McCarthy SW Analysis of histopathological factors associated with prolonged survival of 10 years or more for patients with thick melanomas (>5 mm). klistoparhology33(5), 406–413 (1998).
   Google Scholar
• •Identifies characteristics such as spindle cell phenotype and low mitotic rate that correlate with survival in thick melanomas.
   Google Scholar
• Cascinelli N, Clemente C, Bifulco C etal. Do patients with tumor-positive sentinel nodes constitute a homogeneous group? Ann. Surg Oncol 8\(Suppl. 9), 35S-37S (2001).
   Google Scholar
• Kashani-Sabet M, Sagebiel RVV, Ferreira CM, Nosrati M, Miller JR 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J. Clin. awl 20(7), 1826–1831 (2002).
   Google Scholar
• Mraz-Gernhard S, Sagebiel RVV, Kashani-Sabet M, Miller JR 3rd, Leong SR Prediction of sentinel lymph node micrometastasis by histological features in primary cutaneous malignant melanoma. Arch. Dermatot 134(8), 983–987 (1998).
   Google Scholar
• Ostmeier H, Fuchs B, Otto F etal Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? Cancer 85(11), 2391–2399 (1999).
   Google Scholar
• •Multifactorial analysis utilizing imrnunohistochemical biomarkers did not improve upon conventional multifactorial analysis with clinical and pathologic factors.
   Google Scholar
• Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma, a clinicopathologic analysis of 28 cases. Cancer 75 (2), 478–494 (1995).
   Google Scholar
• Harrist TJ, Rigel DS, Day CL Jr eta]. 'Microscopic satellites' are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer 53 (10), 2183–2187 (1984).
   PubMedGoogle Scholar
• Calonje E. Acp best practice no 162. The histological reporting of melanoma. Association of clinical pathologists. J. Clin. Athol 53(8), 587–590 (2000).
   Google Scholar
• Cochran AJ, H2illy C, Cook Metal. Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Association of directors of anatomic and surgical pathology. Hum. Athol 28(10), 1123–1125 (1997).
   Google Scholar
• Nih consensus conference. Diagnosis and treatment of early melanoma. JAMA 268(10), 1314–1319 (1992).
   PubMedGoogle Scholar
• Ruiter DJ, Spatz A, van den Oord JJ, Cook MG. Pathologic staging of melanoma. Semin. Oncol 29(4), 370–381 (2002).
   Google Scholar
• •Excellent review of current aspects and controversies of pathologic staging.
   Google Scholar
• Busam KJ. Lack of relevant information for tumor staging in pathology reports of primary cutaneous melanoma. Am. J. Clin. Pallid 115 (5), 743–746 (2001) .
   Google Scholar
• •Highlights a need for improved reporting and reproducibility in pathologic reporting of melanoma
   Google Scholar
• Reed JA, Albino AP. Update on diagnostic and prognostic markers in cutaneousmalignant melanoma. Dermatol Clin. 17(3), 631–643 (1999).
   Google Scholar
• •Good review of prognostic factors in melanoma.
   Google Scholar
• Li N, Mangini J, Bhawan J. New prognostic factors of cutaneous melanoma: a review of the literature. J. atm. Pallid 29(6), 324–340 (2002).
   Google Scholar
• •A broad review of prognostic markers for primary melanoma and methods for detecting early metastases.
   Google Scholar
• Kaijalainen JM. Transcription factors and other dysregulated proteins in melanoma prognosis. CUI7: Oncol Rep. 3(4), 368–375 (2001).
   Google Scholar
• ••Excellent review of molecular markers foundto be independent predictors of outcome.
   Google Scholar
• Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta. amyl 38(5), 535–547 (1999).
   Google Scholar
• Bodey B, Kaiser HE, Goldfarb RII. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Rey. 16(1), 517–531 (1996).
   Google Scholar
• Ruiter DJ, van Muijen GN. Markers of melanocytic tumour progression. J. Pallid 186(4), 340–342 (1998).
   Google Scholar
• Stone C, Lynch E, Linden M, Kubus J, Zarbo RJ. Immunohistochemical evaluation of proliferating cell nuclear antigen, ki-67 (mib-1) and p53 in predicting survival of primary and metastatic malignant melanomas. A/A421// 4(1), 25–33 (1996).
   Google Scholar
• Barzilai A, Goldberg I, Yulash M etal Silver-stained nucleolar organizer regions (agnors) as a prognostic value in malignant melanoma. Am. J. Dermatoparhol 20 (5), 473–477 (1998).
   Google Scholar
• Straume 0, Smeds J, Kumar R, Hemminki K, Akslen LA. Significant impact of promoter hypermethylation and the 540 c>t polymorphism of cdkri2a in cutaneous melanoma of the vertical growth phase. Am. J. Farhat 161(1), 229–237 (2002).
   Google Scholar
• •Demonstrates that epigenetic factors and gene polymorphisms also play a role in melanoma pathogenesis and prognosis.
   Google Scholar
• Duncan LM, Deeds J, Cronin FE eta]. Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol 19(2), 568–576 (2001).
   Google Scholar
• •Loss of melastatin in Stage land II independently predicted poor survival. Tests such as this could potentially be used to direct staging investigations and therapy.
   Google Scholar
• Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in Stage I cutaneous malignant melanoma. J. Clin. Oncol 16(11), 3584–3591 (1998).
   Google Scholar
• Vaisanen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T Prognostic value of MMP-2 immunoreactive protein (72 kd Type IV collagenase) in primary skin melanoma. Pathol 186(1), 51–58 (1998).
   Google Scholar
• Healy E, Belgaid C, Takata M eta]. Prognostic significance of allelic losses in primary melanoma. Oncogene 16(17), 2213–2218 (1998).
   PubMedGoogle Scholar
• •Underscores the role of chromosomal instability in the natural history of melanoma as greater loss of alleles independently predicted for poor outcome.
   Google Scholar
• Umebayashi Y, Otsuka E DNA-ploidy abnormalities are a reflection of the metastatic potential of malignant melanoma. Microfluorometric DNA analysis. Acta Derm. livered 77(2), 118–121 (1997).
   Google Scholar
• Grover R, Chana J, Grobbelaar AO et al Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. BE J. Rast. Surg: 52(2), 122–126 (1999).
   Google Scholar
• •High levels of c-Myc oncoprotein independently predicts prognosis in this subgroup of aggressive melanomas.
   Google Scholar
• Bastian BC, Kashani-Sabet M, Hamm H etal Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 60(7), 1968–1973 (2000).
   Google Scholar
• Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 85 (2), 375–382 (1999) .
   PubMed Web of Science ®Google Scholar
• Slominski A, Carlson J, Wortsman J, Mihm MCJ. The role of molecular biology in diagnostic pathology of melanoma. Meth. Mal Medicine 61,123–163 (2001).
   PubMedGoogle Scholar
• Quinn CM, Wright NA The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 160(2), 93–102 (1990).
   PubMedGoogle Scholar
• Cross SS, Start RD. Estimating mitotic activity in tumours. Histopathology29 (5), 485–488 (1996).
   PubMedGoogle Scholar
• Tubiana M, Courdi A. Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother. Oncol 15(1), 1–18 (1989).
   PubMedGoogle Scholar
• Sondergaard K, Schou G. Prognostic factors in primary cutaneous malignant melanoma. Am. J Dermatopathol 7(Suppl.), 1–4 (1985).
   Google Scholar
• MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC. Prognostic models for subgroups of melanoma patients from the Scottish melanoma group database 1979–1986 and their subsequent validation. Br. Cancer 71(1), 173–176 (1995).
   Google Scholar
• Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78(3), 427–432 (1996).
   PubMedGoogle Scholar
• Kopf AW, Gross DF, Rogers GS etal Prognostic index for malignant melanoma. Cancer59(6), 1236–1241 (1987).
   PubMedGoogle Scholar
• Drzewiecki KT, Frydman H, Andersen K etal Malignant melanoma. Changing trends in factors influencing metastasis-free survival from 1964 to 1982. Cancer 65(2), 362–366 (1990).
   Google Scholar
• Vossaert IKA, Silverman MK, Kopf AW etal Influence of gender on survival in patients with Stage I malignant melanoma. Am. Acad. Dermatol 26(3, Pt 2), 429–440 (1992).
   Google Scholar
• van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: interpretation and clinical value. J Clin. Pathol 51(10), 716–724 (1998).
   Google Scholar
• Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R. Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin. Cancer Res. 6(9), 3614–3620 (2000).
   Google Scholar
• Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R. Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195(5), 530–536 (2001).
   PubMedGoogle Scholar
• Florenes VA, Maelandsmo GM, Kerbel RS etal Protein expression of the cell cycle inhibitor p27kipl in malignant melanoma: inverse correlation with disease-free-survival. AIR I Pathol 153(1), 305–312 (1998).
   Google Scholar
• Vogt T, Zipperer KH, Vogt A etal p53- protein and ki-67-antigen expression are both reliable biomarkers of prognosis in thick Stage I nodular melanomas of the skin. Hstopathology 30(1), 57–63 (1997).
   Google Scholar
• Boni R, Doguoglu A, Burg G, Muller B, Dummer R. Mib-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma. jAm Acad. Dermatol 35(3, Pt 1), 416–418 (1996).
   Google Scholar
• Henrique R, Azevedo R, Bento MJ eta]. Prognostic value of ki-67 expression in localized cutaneous malignant melanoma. J Am Acad. Dermatol 43(6), 991–1000 (2000).
   Google Scholar
• Tran TA, Ross JS, Carlson JA, Mihm MC Jr. Mitotic cyclins and cyclin-dependent kinases in melanocytic lesions. Hum. Pathol 29(10), 1085–1090 (1998).
   Google Scholar
• Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan. Pathol 23(4), 335–343 (1996).
   Google Scholar
• Reddy VB, Gattuso P, Aranha G, Carson HJ. Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan. Pathol 22(3), 248–251 (1995).
   Google Scholar
• Castellano M, Parmiani G. Genes involved in melanoma: an overview of INK4a and other loci. 1141anoma Res. 9(5), 421–432 (1999).
   Google Scholar
• Maelandsmo GM, Florenes VA, Hovig E etal Involvement of the prb/p16/cdk4/ cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. BE J Cancer73(8), 909–916 (1996).
   Google Scholar
• Bartkova J, Lukas J, Guldberg P etal The p16-cyclin d/CDK4-prb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res. 56(23), 5475–5483 (1996).
   Google Scholar
• Funk JO, Schiller PI, Barrett MT etal p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan. Pathol 25(6), 291–296 (1998).
   Google Scholar
• Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21wAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. J Dermatopathol 20(3), 255–261 (1998).
   Google Scholar
• Reed JA, Loganzo F Jr, Shea CR eta]. Loss of expression of the p16/cyclin-dependent kinase inhibitor-2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 55(13), 2713–2718 (1995). iii Talve L, Sauroja I, Collan Y, Punnonen K, K Ekfors T Loss of expression of the p161-Al CDIKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. int. J Cancer74(3), 255–259 (1997).
   Google Scholar
• Pavey SJ, Cummings MC, Whiteman DC etal I nss of p16 expression is associated with histological features of melanoma invasion. 1141anoma Res. 12(6), 539–547 (2002).
   Google Scholar
• Hunter JJ, Shao J, Smutko JS eta]. Chromosomal localization and genomic characterization of the mouse melastatin gene (mlsnl) . Genomics 54 (1), 116–123 (1998).
   PubMedGoogle Scholar
• Ferrier CM, van Muijen GN, Ruiter DJ. Proteases in cutaneous melanoma. Ann. Med. 30(5), 431–442 (1998).
   PubMed Web of Science ®Google Scholar
• Vaisanen A, Tuominen H, Kallioinen M, Turpeenniemi-Hujanen T Matrix metalloproteinase-2 (72 kd type iv. collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. I Pathol 180(3), 283–289 (1996).
   Google Scholar
• Mitelman F, Johansson B, Mertens Catalog of Chromosome Aberrations in Cancer Wiley-Liss, NY, USA (1994).
   Google Scholar
• Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. Karyotypic evolution in human malignant melanoma. Cancer Genet. Cytogenet. 19(1-2), 113–122 (1986).
   Google Scholar
• Fabarius A, Willer A, Yerganian G, Hehlmann R, Duesberg P Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. Doc. Natl Acad. Li. USA 99(10), 6778–6783 (2002).
   Google Scholar
• Nelson MA, Radmacher MD, Simon R et al Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet. Cytogenet. 122(2), 101–109 (2000).
   Google Scholar
• Miele ME, Robertson G, Lee JH etal Metastasis suppressed but tumorigenicity and local invasiveness unaffected, in the human melanoma cell line meljuso after introduction of human chromosomes 1 or 6. Mal Carrinog. 15(4), 284–299 (1996).
   Google Scholar
• Udart M, Utikal J, Krahn GM, Peter RU. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 3 (3), 245–254 (2001).
   Google Scholar
• Rao U, Jones MW Finkelstein SD. Genotypic anlysis of primary and metastatc cutaneous melanoma. Cancer Genet. Cytogenet. 140,37–44 (2003).
   PubMed Web of Science ®Google Scholar
• Scheistroen M, Trope C, Koem J etal Malignant melanoma of the vulva. Evaluation of prognostic factors with emphasis on DNA ploidy in 75 patients. Cancer 75 (1), 72–80 (1995) .
   Google Scholar
• Kheir SM, Bines SD, Vonroenn JH etal Prognostic significance of DNA aneuploidy in Stage I cutaneous melanoma. Ann. Surg: 207(4), 455–461 (1988).
   PubMed Web of Science ®Google Scholar
• Agarwala SS. Intermediate- and high-risk melanoma. Curl: Treat. Options Oncol 3(3), 205–217 (2002).
   PubMedGoogle Scholar
• Szymik B, Woosley JT. Further validation of the prognostic model for Stage I malignant melanoma based on tumor progression. j Cutan. Pathol 20(1), 50–53 (1993).
   Google Scholar
• Cochran AJ, Elashoff D, Morton DL, Elashoff R. Individualized prognosis for melanoma patients. Hum. Pathol 31(3), 327–331 (2000).
   PubMedGoogle Scholar
• •Developed a two-step multifactorial formula (based on the five variables: gender, age, anatomical site, thickness and ulceration) to determine likelihood for recurrence of melanoma using readily available demographic information.
   Google Scholar
• Bockmann B, Grill HJ, Giesing M. Molecular characterization of minimal residual cancer cells in patients with solid tumors. Biomol Eng. 17(3), 95–111 (2001).
   PubMedGoogle Scholar
• Meier F, Will S, Ellwanger U etal Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br. Dermatol 147 (1), 62–70 (2002).
   PubMedGoogle Scholar
• Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE etal Metastatic patterns, clinical outcome and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 38(5), 549–557 (1999).
   PubMedGoogle Scholar
• Statius Muller MG, Van Leeuwen PA, Van Diest PJ etal Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients. World Surg: 26(12), 1405–1411 (2002).
   PubMedGoogle Scholar
• •Sentinel lymph node procedure affects patterns of recurrent disease.
   Google Scholar
• Kelly RV, Blois MS, Sagebiel RVV. Frequency and duration of patient follow-up after treatment of a primary malignant melanoma. jAm. Acad. Dermatol 13(5, Part 1), 756–760 (1985).
   Google Scholar
• Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in Stage I cutaneous malignant melanoma: an audit. Clin. Oncol (2?. Coll. Radio), 5(3), 174–180 (1993).
   Google Scholar
• Martini L, Brandani P, Chiarugi C, Reali UM. First recurrence analysis of 840 cutaneous melanomas: a proposal for a follow-up schedule. Tumori 80 (3), 188–197 (1994).
   Google Scholar
• Shumate CR, Urist MM, Maddox WA. Melanoma recurrence surveillance. Patient or physician based? Ann. Surg: 221(5), 566–569 (1995).
   Google Scholar
• Basseres N, Grob JJ, Richard MA etal Cost-effectiveness of surveillance of Stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatol 191(3), 199–203 (1995).
   Google Scholar
• Johnson TM, Smith RV 2nd, Nelson BR, Chang A. Current therapy for cutaneous melanoma. jAm. Acad. Dermatol 32(5, Part 1), 689–707 (1995).
   Google Scholar
• Griego RD, Zitelli JA. Management of Stage I malignant melanoma. Dermatol Surg: 22(8), 730–733 (1996).
   PubMedGoogle Scholar
• Brobeil A, Rapaport D, Wells K etal Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann. Surg: Oncol 4(1), 19–23 (1997).
   PubMedGoogle Scholar
• Mooney MM, Kulas M, McKinley B, Michalek AM, Kraybill WG. Impact on survival by method of recurrence detection in Stage I and II cutaneous melanoma. Ann. Surg. Oncol 5(1), 54–63 (1998).
   Google Scholar
• Dicker TJ, Kavanagh GM, Herd RM et al A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish melanoma group. BE j Dermatol 140(2), 249–254 (1999).
   PubMedGoogle Scholar
• Epstein DS, Lange JR, Gruber SB, Mond M, Koch SE. Is physician detection associated with thinner melanomas?JAIVIA 281(7), 640–643 (1999).
   Google Scholar
• Johnson TM, Chang A, Redman B etal Management of melanoma with a multidisciplinary melanoma clinic model. Am. Acad. Dermatol 42(5, Part 1), 820–826 (2000).
   Google Scholar
• Cordel N, Safa G, Balguerie X etal. In-patient and out-patient follow-up of grade I malignant melanoma. Ann. Dermatol Tivemol. 127(6–7), 579–583 (2000).
   Google Scholar
• Poo-Hwu WJ, Ariyan S, Lamb L etal Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer 86(11), 2252–2258 (1999).
   PubMedGoogle Scholar
• Gamel JW, George SL, Edwards MJ, Seigler HE The long-term clinical course of patients with cutaneous melanoma. Cancer 95(6), 1286–1293 (2002).
   PubMedGoogle Scholar
• Schmid-Wendtner MET, Baumert J, Schmidt M etal Late metastases of cutaneous melanoma: an analysis of 31 patients. jAm. Acad. Dermatol 43 (4), 605–609 (2000).
   Google Scholar
• Shaw H, Thompson J, McCarthy W Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 82(9), 1799–1800 (1998).
   Google Scholar
• Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79(12), 2361–2370 (1997).
   Google Scholar
• Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann. Sing 212(2), 173–177 (1990).
   Google Scholar
• Damian DL, Fulham MJ, Thompson E, Thompson JE Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 6(4), 325–329 (1996).
   Google Scholar
• Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J. Am. Acad. Dermatol 38(5, Pt 1), 669–680 (1998).
   Google Scholar
• Hsueh EC, Gupta RK, Glass EC eta]. Positron emission tomography plus serum ta90 immune complex assay for detection of occult metastatic melanoma. J. Am. Coll. Surg. 187(2), 191–197 (1998).
   Google Scholar
• VOit C, Schoengen A, Schwurzer-Voit M etal The role of ultrasound in detection and management of regional disease in melanoma patients. Semin. Oncol 29(4), 353–360 (2002).
   PubMedGoogle Scholar
• Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann. Suzy 227(5), 764–769 (1998).
   PubMedGoogle Scholar
• Blum A, Schlagenhauff B, Stroebel W etal Ultrasound examination of regional lymph nodes significantly improves early detection of locoregional metastases during the follow-up of patients with cutaneous melanoma: results of a prospective study of 1288 patients. Cancer88(11), 2534–2539 (2000).
   Google Scholar
• Wagner JD, Schauwecker D, Davidson D etal Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J. Clin. Oncol 17(5), 1508–1515 (1999).
   Google Scholar
• Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin. Nucl. Med. 25(1), 48–51 (2000).
   Google Scholar
• Mijnhout GS, Hoekstra OS, van Tulder MW Teule GJ, Deville WL. Systematic review of the diagnostic accuracy of (18)f-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer 91(8), 1530–1542 (2001).
   Google Scholar
• Schwimmer J, Essner R, Patel A et al A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q. J. Nucl. Med. 44(2), 153–167 (2000).
   Google Scholar
• Acland KM, O'Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J. Am. Acad. Dermatol 42(4), 606–611 (2000).
   Google Scholar
• Kalff V, Hicks RJ, Ware RE et a/. Evaluation of high-risk melanoma: comparison of [18F1 FDG PET and high-dose 67ga SPET. Eur. J. Nucl. Med. Mal Imaglng29(4), 506–515 (2002).
   Google Scholar
• Landi G, Landi C. The sentinel node biopsy in melanoma patients. Delmatol NUTS. 13(6), 429–434,441 (2001).
   Google Scholar
• Morton DL, Wen DR, Wong JH etal. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch. Surg. 127(4), 392–399 (1992).
   Google Scholar
• Krag DN, Weaver DL. Pathological and molecular assessment of sentinel lymph nodes in solid tumors. Semin. Oncol 29(3), 274–279 (2002).
   PubMedGoogle Scholar
• Chan AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J. Am. Coll. Surg. 191(1), 16–22 (2000).
   Google Scholar
• Blaheta HJ, Schittek B, Breuninger H, Garbe C. Detection of micrometastasis in sentinel lymph nodes of patients with primary cutaneous melanoma. Recent Results Cancer Res. 158,137–146 (2001).
   PubMedGoogle Scholar
• Dessureault S, Soong SJ, Ross MI etal Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann. SLIT Oncol 8(10), 766–770 (2001).
   Google Scholar
• Thelmo MC, Sagebiel RVV, Treseler PA etal Evaluation of sentinel lymph node status in spindle cell melanomas. J. Am. Acad. Dermatol 44(3), 451–455 (2001).
   Google Scholar
• Gibbs JF, Huang PP, Zhang PJ, Kraybill WG, Cheney R. Accuracy of pathologic techniques for the diagnosis of metastatic melanoma in sentinel lymph nodes. Ann. Surg. Oncol 6(7), 699–704 (1999).
   Google Scholar
• Bonin S, Niccolini B, Calacione R eta]. Molecular analyses of sentinel lymph nodes: an open question. J. Eur. Acad. Dermatol Venemol 16(1), 34–39 (2002).
   Google Scholar
• Shivers SC, Li W Lin J etal The clinical relevance of molecular staging for melanoma. Recent Results Cancer Res. 158, 187–199 (2001).
   PubMedGoogle Scholar
• •Excellent study comparing routine versus molecular (RT-PCR) assessment of sentinel lymph nodes.
   Google Scholar
• Cochran AJ. The pathologist's role in sentinel lymph node evaluation. Semin. Nucl. Med. 30(1), 11–17 (2000).
   Google Scholar
• Baisden BL, Askin FB, Lange JR, Westra WH. Hmb-45 immunohistochemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. A117. I Surg. Radial 24(8), 1140–1146 (2000).
   Google Scholar
• Yu LL, Flotte TJ, Tanabe KK eta]. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 86(4), 617–627 (1999).
   PubMed Web of Science ®Google Scholar
• Cochran AJ, Huang RR, Guo J, Wen DR. Current practice and future directions in pathology and laboratory evaluation of the sentinel node. Ann. Surg. Oncol 8\(Suppl. 9), 135–175 (2001).
   Google Scholar
• Lukowsky A, Bellmann B, Ringk A eta]. Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J. Invest. Dermatol 113 (4), 554–559 (1999).
   Google Scholar
• Blaheta HJ, Ellwanger U, Schittek B etal Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J. Invest. Dermatol 114(4), 637–642 (2000).
   Google Scholar
• Davids V, Kidson SH, Hanekom GS. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity and detection rate. Mal Pathol 56(1), 43–51 (2003).
   PubMedGoogle Scholar
• Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD. Expression of tyrosinase, MIA and mart-1 in sentinel lymph nodes of patients with malignant melanoma. BE j Dermatol 146(2), 244–249 (2002).
   Google Scholar
• Li W Stall A, Shivers SC etal. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann. Sing. 231(6), 795–803 (2000).
   Google Scholar
• Shivers SC, Wang X, Li W etal Molecular staging of malignant melanoma: correlation with clinical outcome. JAIVIA 280(16), 1410–1415 (1998).
   PubMed Web of Science ®Google Scholar
• Hauschild A, Christophers E. Sentinel node biopsy in melanoma. Vfirhowskrh. 438(2), 99–106 (2001).
   Google Scholar
• Bautista NC, Cohen S, Anders KH. Benign melanocytic nevus cells in axillary lymph nodes. A prospective incidence and immunohistochemical study with literature review. AM. j Clin. Pathol 102 (1), 102–108 (1994).
   Google Scholar
• Blaheta HJ, Schittek B, Breuninger H etal Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. int. j Cancer 79(4), 318–323 (1998).
   PubMedGoogle Scholar
• Bostick PJ, Morton DL, Turner RR eta]. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. Clin. Oncol 17(10), 3238–3244 (1999).
   Google Scholar
• Calogero A, Hospers GA, Timmer-Bosscha H, Koops HS, Mulder NH. Effect of specific or random c-DNA priming on sensitivity of tyrosinase nested RT-PCR: potential clinical relevance. Anticancer Res. 20(5B), 3545–3548 (2000).
   Google Scholar
• Calogero A, Timmer-Bosscha H, Schraffordt Koops H et al Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes. BE Cancer83(2), 184–187 (2000).
   Google Scholar
• Carson KF, Wen DR, Li PX eta]. Nodal nevi and cutaneous melanomas. Am. Surg. Pathol 20(7), 834–840 (1996).
   Google Scholar
• Blaheta HJ, Schittek B, Breuninger H eta]. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Ainj Surg. Pathol 23(7), 822–828 (1999).
   Google Scholar
• Wang X, Heller R, VanVoorhis N et al Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann. Surg. 220(6), 768–774 (1994).
   PubMed Web of Science ®Google Scholar
• Riccioni L, Farabegoli P, Nanni 0 etal The sentinel lymph node in melanoma: utilization of molecular biology (RT-PCR) to detect occult metastases. Pathologica 94(4), 190–195 (2002).
   Google Scholar
• Lohmann CM, Iversen K, Jungbluth AA, Berwick M, Busam KJ. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am. Surg. Pathol 26(10), 1351–1357 (2002).
   Google Scholar
• Slominski A. Coming of age of melanogenesis-related proteins. Arch. Pathol Lab. Merl 126(7), 775–777 (2002).
   Google Scholar
• Grossman D, McNiff JM, Li F, Alfieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. j Invest. Dermatol 113(6), 1076–1081 (1999).
   Google Scholar
• Gradilone A, Gazzaniga P, Ribuffo D eta]. Survivin, bc1-2, bax and bcl-x gene expression in sentinel lymph nodes from melanoma patients. j Clin. Oncol 21(2), 306–312 (2003).
   Google Scholar
• van der Velde-Zimmermann D, Schipper ME, de Weger RA, Hennipman A, Borel Rinkes IH. Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann. Surg. Oncol 7(1), 51–54 (2000).
   Google Scholar
• Santin AD. Lymph node metastases: the importance of the microenvironment. Cancer 88 (1), 175–179 (2000) .
   PubMedGoogle Scholar
• Joseph E, Brobeil A, Glass F eta]. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann. Surg. Oncol 5(2), 119–125 (1998).
   Google Scholar
• Starz H, Balda BR, Kramer KU, Buchels H, Wang H. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer91(11), 2110–2121 (2001).
   PubMed Web of Science ®Google Scholar
• Beastall GH, Cook B, Rustin GJ, Jennings J. A review of the role of established tumour markers. Ann. Clin. Biochem. 28\(Pt 1), 5–18 (1991).
   Google Scholar
• Brochez L, Naeyaert JM. Serological markers for melanoma. BE j Dermatol 143(2), 256–268 (2000).
   PubMedGoogle Scholar
• •Broad review of blood biomarkers of metastatic disease.
   Google Scholar
• Hauschild A, Glaser R, Christophers E. Quantification of melanoma-associated molecules in plasma/serum of melanoma patients. Recent Results Cancer Res. 158, 169–177 (2001).
   PubMedGoogle Scholar
• Reinhold U, Ludtke-Handjery HC, Schnautz S, Kreysel HW, Abken H. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. j Invest. Dermatol 108(2), 166–169 (1997).
   Google Scholar
• Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment and recurrence from melanoma. j Clin. Oncol 16(5), 1760–1769 (1998).
   Google Scholar
• Smith B, Selby P, Southgate J etal Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 338(8777), 1227–1229 (1991).
   PubMed Web of Science ®Google Scholar
• Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Atch. Dermatol 137(3), 325–330 (2001).
   PubMedGoogle Scholar
• •Suggests that the use of this test as a prognostic indicator rather than a staging procedure might improve the utility of this molecular serologic tool at present.
   Google Scholar
• Curry BJ, Myers K, Hersey P Utility of tests for circulating melanoma cells in identifying patients who develop recurrent melanoma. Recent Results Cancer Res. 158, 211–230 (2001).
   PubMedGoogle Scholar
• Guidi B, Diociaiuti A, Capizzi R et al Increased s1 00b serum levels in diffuse dermatitis. Melanoma Res. 12(6), 633 (2002).
   Google Scholar
• Szenajch J, Jasinski B, Kozak A etal Multiple RT-PCR tyrosinase testing reveals that melanoma cells circulate in the blood of melanoma patients at the frequency more than ten-times below the detection threshold. Melanoma Res. 12(4), 399–401 (2002).
   Google Scholar
• •Blood volume sample size and high thresholds for detection may explain false-negatives to date for RT-PCR
   Google Scholar
• Denis MG, Masson D, Tessier MET, Dreno B, Lustenberger P Sampling and the detection of melanoma cells in blood. Melanoma Res. 12(3), 291–292 (2002).
   Google Scholar
• Max N, Wolf K, Thiel E, Keilholz U. Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease. Clin. Chim. Acta317 (1–2), 39–46 (2002).
   Google Scholar
• Georgieva J, Milling A, Orfanos CE, Geilen CC. Magnetic bead RT-PCR: establishment of a new method for detecting circulating melanoma cells. Melanoma Res. 12(4), 309–317 (2002).
   Google Scholar
• Siewert C, Herber M, Hunzelmann N etal Rapid enrichment and detection of melanoma cells from peripheral blood mononuclear cells by a new assay combining immunomagnetic cell sorting and immunocytochemical staining. Recent Results Cancer Res. 158, 51–60 (2001).
   PubMedGoogle Scholar
• Moore BW. Chemistry and biology of the s-100 protein. Scand. j Ihenunal 9(Suppl.), 53–74 (1982).
   Google Scholar
• Guo H, Stoffel-Wagner B, Bierwierth T, Mezger J, Klingmuller U. Clinical significance of serum analyses of s1 00I3 protein in malignant melanoma. Eur Cancer31A, 924–928 (1995).
   PubMedGoogle Scholar
• Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum s100: a marker for disease monitoring in metastatic melanoma. Dermatology194 (3), 208–212 (1997) .
   Google Scholar
• Kaskel P, Berking C, Sander S eta]. 5–100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. jAm. Acad. Dermatol 41 (6), 962–969 (1999).
   Google Scholar
• Jury CS, McAllister EJ, MacKie RM. Rising levels of serum sl 00 protein precede other evidence of disease progression in patients with malignant melanoma. BE Dermatol 143(2), 269–274 (2000).
   Google Scholar
• Schultz ES, Diepgen TL, von Den Driesch P. Clinical and prognostic relevance of serum s-100 3 protein in malignant melanoma. BE j Dermatol 138(3), 426–430 (1998).
   Google Scholar
• Hauschild A, Michaelsen J, Brenner W etal Prognostic significance of serum s10013 detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 9(2), 155–161 (1999).
   Google Scholar
• Hansson LO, von Schoultz E, Djureen E etal Prognostic value of serum analyses of s-100 protein 3 in malignant melanoma. Anticancer Res. 17(4B), 3071–3073 (1997).
   Google Scholar
• von Schoultz E, Hansson LO, Djureen E etal Prognostic value of serum analyses of s-100 3 protein in malignant melanoma. Melanoma Res. 6(2), 133–137 (1996).
   Google Scholar
• Hauschild A, Engel G, Brenner W etal S1000 protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56 (4), 338–344 (1999).
   Google Scholar
• Meral R, Duranyildiz D, Tas F etal Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 11(6), 627–632 (2001).
   Google Scholar
• Krahn G, Kaskel P, Sander S etal S100I3 is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 21 (2B), 1311–1316 (2001).
   Google Scholar
• Hauschild A, Engel G, Brenner W etal Predictive value of serum s1 00I3 for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. BE j Dermatol 140(6), 1065–1071 (1999).
   Google Scholar
• Juergensen A, Holzapfel U, Hein R etal Comparison of two prognostic markers for malignant melanoma: MIA and s100-I3. Tumour Bid 22(1), 54–58 (2001).
   Google Scholar
• Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay s-100: a sensitive test to measure circulating s-10013: its prognostic value in malignant melanoma. BE j Cancer 77(12), 2210–2214 (1998).
   Google Scholar
• Stoitchkov K, Letellier S, Gamier JP etal Melanoma progression and serum L-dopa/ L-tyrosine ratio: a comparison with s10013. Melanoma Res. 12(3), 255–262 (2002).
   Google Scholar
• Bosserhoff AK, Hein R, Bogdahn U, Buettner R. Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA. j Biol. Chem. 271(1), 490–495 (1996).
   Google Scholar
• Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A. Comparative study on the clinical use of protein s-1 00I3 and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res. 20 (6D), 5059–5063 (2000).
   Google Scholar
• Gupta RK. Circulating immune complexes in malignant melanoma. Dis. Markers 6(2), 81–95 (1988).
   PubMedGoogle Scholar
• Kelley MC, Gupta RK, Hsueh EC etal Tumor-associated antigen ta90 immune complex assay predicts recurrence and survival after surgical treatment of Stage I-III melanoma. j Clin. Once'. 19(4), 1176–1182 (2001).
   Google Scholar
• Chung MH, Gupta RK, Essner R etal Serum ta90 immune complex assay can predict outcome after resection of thick mm) primary melanoma and sentinel lymphadenectomy. Ann. Sorg. Once'. 9(2), 120–126 (2002).
   Google Scholar
• •This test stratifies patients with Stage II and III melanoma into high- and low-risk groups in the early post treatment period.
   Google Scholar
• Agrup G, Agrup P, Andersson T eta]. 5 years' experience of 5-s-cysteinyldopa in melanoma diagnosis. Acta Derm. Venereal 59(5), 381–388 (1979).
   Google Scholar
• Peterson LL, Woodward WR, Fletcher WS eta]. Plasma 5-s-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects. jAm. Acad. Dermatol 19 (3), 509–515 (1988).
   Google Scholar
• Hara H, Walsh N, Yamada K, Jimbow K. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma.j Invest. Dermatol 102 (4), 501–505 (1994).
   Google Scholar
• Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 73 (3), 629–636 (1994).
   PubMedGoogle Scholar
• Karnell R, von Schoultz E, Hansson LO etal sloop protein, 5-s-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Mianoma Res. 7(5), 393–399 (1997).
   Google Scholar
• Hasegawa M, Takata M, Hatta N etal Simultaneous measurement of serum 5-s-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma. Melanoma Res. 7(3), 243–251 (1997).
   Google Scholar
• Wimmer I, Meyer JC, Seifert B et al. Prognostic value of serum 5-s-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 57(22), 5073–5076 (1997).
   Google Scholar
• Sasaki Y, Shimizu H, Naka W, Takeshita E, Nishikawa T Evaluation of the clinical usefulness of measuring urinary excretion of 5-s-cysteinyldopa in melanoma: 10 years' experience of 50 patients. Acta Derm. linen-al 77(5), 379–381 (1997).
   Google Scholar
• Hirai S, Kageshita T, Kimura T eta]. Serum levels of sicam-1 and 5-s-cysteinyldopa as markers of melanoma progression. Melanoma Res. 7(1), 58–62 (1997).
   Google Scholar
• Karnell R, Kagedal B, Lindholm C etal The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res. 10(4), 363–369 (2000).
   Google Scholar
• Matsushita Y, Hatta N, Wakamatsu K eta]. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-s-cysteinyldopa. Melanoma Res. 12(4), 319–323 (2002).
   Google Scholar
• Wakamatsu K, Kageshita T, Fume M etal Evaluation of 5-s-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res. 12 (3), 245–253 (2002).
   Google Scholar
• Banfalvi T, Gilde K, Boldizsar M, Kremmer T Clinical significance of 5-s-cysteinyldopa monitoring in patients with malignant melanoma. Neoplasma 49 (2), 121–125 (2002).
   Google Scholar
• Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 63(2), 441–448 (2003).
   PubMed Web of Science ®Google Scholar
• Keilholz U, Willhauck M, Scheibenbogen C, de Vries TJ, Burchill S. Polymerase chain reaction detection of circulating tumour cells. EORTC melanoma co-operative group, immunotherapy subgroup. Melanoma Res. 7\(Suppl. 2), S133-141 (1997).
   Google Scholar
• Brossart P, Keilholz U, Willhauck M eta]. Hematogenous spread of malignant melanoma cells in different stages of disease. .1. Invest. Dermatol 101 (6), 887–889 (1993).
   Google Scholar
• Palmieri G, Strazzullo M, Ascierto PA eta]. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma co-operative group. j Clin. aryl 17(1), 304–311 (1999).
   Google Scholar
• Mellado B, Colomer D, Castel T eta]. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis.J Clin. Oncol 14(7), 2091-2097 (1996).
   Google Scholar
• Battayani Z, Grob JJ, Xerri L eta]. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch. Dermatol 131(4), 443–447 (1995).
   Google Scholar
• Farthmann B, Eberle J, Krasagakis K eta]. RT-PCR for tyrosinase-mRNA-positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. Invest. Dermatol 110(3), 263–267 (1998).
   Google Scholar
• Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epiclemiol Biomarkers Prey. 5(4), 293–296 (1996).
   PubMed Web of Science ®Google Scholar
• Hoon DS, Bostick P, Kuo C eta]. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60(8), 2253–2257 (2000).
   PubMed Web of Science ®Google Scholar
• Jung FA, Buzaid AC, Woods KV, Ross M, Grimm EA. Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction assay for tyrosinase mRNA. Cancer Surv. 26, 251–265 (1996).
   Google Scholar
• Berteau P, Dumas F, Gala JL etal Influence of blood storage and sample processing on molecular detection of circulating prostate cells in cancer. Cl/n. Chem. 44(3), 677–679 (1998).
   Google Scholar
• Schrader AJ, Probst-Kepper M, Grosse J etal Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 10(4), 355–362 (2000).
   Google Scholar
• Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of melana messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. BE Dermatol 141(1), 30–36 (1999).
   PubMedGoogle Scholar
• Sarantou T, Chi DD, Garrison DA eta]. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 57(7), 1371–1376 (1997).
   PubMedGoogle Scholar
• Shen J, Wallace AM, Bouvet M. The role of sentinel lymph node biopsy for melanoma. Semin. aryl 29(4), 341–352 (2002).
   Google Scholar
• Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin. Surg. Oncol 8(6), 400–414 (1992).
   Google Scholar
• Morton DL, Davtyan DG, Wanek LA, Foshag LJ, Cochran AJ. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by clark level and breslow thickness. Cancer 71(11), 3737–3743 (1993).
   PubMedGoogle Scholar
• Gamel JW, George SL, Stanley WE, Seigler HE Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age and sex. Cancer 72 (4), 1219–1223 (1993).
   PubMedGoogle Scholar
• Thorn M, Ponten F, Bergstrom R, Sparen P, Adami HO. Trends in tumour characteristics and survival of malignant melanoma 1960–84: a population-based study in Sweden. BE j Cancer 70 (4), 743–748 (1994).
   Google Scholar
• Karakousis CP, Driscoll DL. Prognostic parameters in localised melanoma: gender versus anatomical location. Eur. j Cancer 31A(3), 320–324 (1995).
   PubMedGoogle Scholar
• Helfenstein U, Schuler G, Morf S, Schuler D. Action profiles of predictors of death and survival time in Stage I malignant melanoma. Dermatology192 (1), 1–7 (1996).
   PubMedGoogle Scholar
• Schuchter L, Schultz DJ, Synnestvedt M et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The pigmented lesion group. Ann. Intern. Med. 125(5), 369–375 (1996).
   Google Scholar
• Averbook BJ, Russo LJ, Mansour EG. A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 124(4), 746–755 (1998).
   Google Scholar
• Levi F, Randimbison L, La Vecchia C, Te VC, Franceschi S. Prognostic factors for cutaneous malignant melanoma in Vaud, Switzerland. Int.j Cancer 78(3), 315–319 (1998).
   Google Scholar
• Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic COX regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging. Surgery 132 (4), 589–602 (2002).
   Google Scholar
• Cascinelli N, Morabito A, Bufalino R etal Prognosis of Stage I melanoma of the skin. WHO collaborating centers for evaluation of methods of diagnosis and treatment of melanoma. Int.j Cancer26, 733–739 (1980).
   Google Scholar
• Lens MB, Dawes M, Goodacre T, Bishop JA. Excision margins in the treatment of primary cutaneous melanoma: a systematic review of randomized controlled trials comparing narrow versus wide excision. Arch. Surg. 137(10), 1101–1105 (2002).
   PubMedGoogle Scholar
• McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. BE Dermatol 147(1), 48–54 (2002).
   PubMedGoogle Scholar
• Stadelamann W Rapaport D, Soong S et al Prognostic clinical and pathologic features. In: Cutaneous melanoma. Balch CM, Houghton A, Sober A, Soong S (Eds) Quality Medical Publishing Inc., St. Louis, MO, USA, 11–35 (1998).
   Google Scholar
• Buzaid AC, Ross MI, Balch CM eta]. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J. Gun. Oncol 15(3), 1039–1051 (1997).
   Google Scholar
• Clemente CG, Mihm MC, Jr, Bufalino R etal Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77(7), 1303–1310 (1996).
   PubMed Web of Science ®Google Scholar
• Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanomasmm): identification of risk factors indicative of progression. Cancer 85(5), 1067–1076 (1999).
   PubMedGoogle Scholar
• Leon P, Daly JM, Synnestvedt M etal The prognostic implications of microscopic satellites in patients with clinical Stage I melanoma. Arch. Surg. 126 (12), 1461–1468 (1991).
   PubMedGoogle Scholar
• Kuchelmeister C, Schaumburg-Lever G, Garbe C. Acral cutaneous melanoma in Caucasians: clinical features, histopathology and prognosis in 112 patients. BE J. Dermatol 143(2), 275–280 (2000).
   Google Scholar
• Quinn MJ, Crotty IKA, Thompson JF etal Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer83(6), 1128–1135 (1998).
   Google Scholar
• Niezabitowski A, Czajecki K, Rys J etal Prognostic evaluation of cutaneous malignant melanoma: a clinicopathologic and immunohistochemical study. I Surg: Oncol 70(3), 150–160 (1999).
   PubMedGoogle Scholar
• Karjalainen JM, Eskelinen MJ, Kellokoski JK et al P21(wan/cipl) expression in Stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br Cancer79(5–6), 895–902 (1999).
   Google Scholar
• Essner R, Kuo CT, Wang H etal Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites. Cancer 82 (2), 309–316 (1998) .
   Google Scholar
• Salti GI, Manougian T, Farolan M etal Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 60(18), 5012–5016 (2000).
   Google Scholar
• Demunter A, Ahmadian MR, Libbrecht L etal A novel n-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61 (12), 4916–4922 (2001).
   Google Scholar
• Sugita K, Yamamoto 0, Asahi M. Immunohistochemical analysis of metallothionein expression in malignant melanoma in Japanese patients. Am. J. Delmatopathol 23(1), 29–35 (2001).
   Google Scholar
• Karjalainen JM, Tammi RII, Tammi MI etal Reduced level of cd44 and hyaluronan associated with unfavorable prognosis in clinical Stage I cutaneous melanoma. Am. J. Pallid 157(3), 957–965 (2000).
   Google Scholar
• Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pallid 30(3), 339–344 (1999).
   Google Scholar
• Ferrier CM, Suciu S, van Geloof WL etal High tPA-expression in primary melanoma of the limb correlates with good prognosis. BE J. Cancer 83(10), 1351–1359 (2000).
   Google Scholar
• Huang X, Soong S, McCarthy WH, Urist MM, Balch CM. Classification of localized melanoma by the exponential survival trees method. Cancer 79(6), 1122–1128 (1997).
   PubMedGoogle Scholar
• Landi G, Polverelli M, Moscatelli G etal Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. J. Eur. Acad. Dermatol Venemol 14(1), 35–45 (2000).
   Google Scholar
• Bosserhoff AK, Lederer M, Kaufmann M etal MIA, a novel serum marker for progression of malignant melanoma. Anticancer Res. 19(4A), 2691–2693 (1999).
   Google Scholar
• Reintgen DS, Cruse CW, Wells KE, Saba HI, Fabri PJ. The evaluation of putative tumor markers for malignant melanoma. Ann. Rast. Surg. 28(1), 55–59 (1992).
   Google Scholar
• Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T etal Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma. BE J. Cancer 83(7), 847–852 (2000).
   Google Scholar
• Osella-Abate S, Quaglino P, Savoia P et al VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res. 12(4), 325–334 (2002).
   Google Scholar
• Franzke A, Probst-Kepper M, Buer J etal Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br. Cancer 78 (1), 40–45 (1998).
   Google Scholar
• Mellado B, Gutierrez L, Castel T etal Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin. Cancer Res. 5(7), 1843–1848 (1999).
   PubMedGoogle Scholar
• Chan AD, Morton DL. Sentinel node detection in malignant melanoma. Recent Results Cancer Res. 157,161–177 (2000).
   PubMedGoogle Scholar
• Duncan LM, Deeds J, Cronin FE et al Melastatin expression and prognosis in cutaneous malignant melanoma. J. Clin. Oncol 19(2), 568–576 (2001).
   Google Scholar